Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
Yuen MF, Heo J, Kumada H, Suzuki F, Suzuki Y, Xie Q, Jia J, Karino Y, Hou J, Chayama K, Imamura M, Lao-Tan JY, Lim SG, Tanaka Y, Xie W, Yoon JH, Duan Z, Kurosaki M, Park SJ, Labio ME, Kumar R, Kweon YO, Yim HJ, Tao Y, Cremer J, Elston R, Davies M, Baptiste-Brown S, Han K, Campbell FM, Paff M, Theodore D. Yuen MF, et al. Among authors: paff m. J Hepatol. 2022 Oct;77(4):967-977. doi: 10.1016/j.jhep.2022.05.031. Epub 2022 Jun 15. J Hepatol. 2022. PMID: 35714812 Free article. Clinical Trial.
A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
Han K, Cremer J, Elston R, Oliver S, Baptiste-Brown S, Chen S, Gardiner D, Davies M, Saunders J, Hamatake R, Losos J, Leivers M, Hood S, van der Berg F, Paff M, Ritter JM, Theodore D. Han K, et al. Among authors: paff m. Clin Pharmacol Drug Dev. 2019 Aug;8(6):790-801. doi: 10.1002/cpdd.670. Epub 2019 Mar 12. Clin Pharmacol Drug Dev. 2019. PMID: 30861337 Free PMC article. Clinical Trial.
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, Tami Y, You S, Yates P, Tao Y, Cremer J, Campbell F, Elston R, Theodore D, Paff M, Bennett CF, Kwoh TJ. Yuen MF, et al. Among authors: paff m. Nat Med. 2021 Oct;27(10):1725-1734. doi: 10.1038/s41591-021-01513-4. Epub 2021 Oct 12. Nat Med. 2021. PMID: 34642494 Free PMC article. Clinical Trial.
Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses.
Han K, Theodore D, McMullen G, Swayze E, McCaleb M, Billioud G, Wieland S, Hood S, Paff M, Bennett CF, Kwoh TJ. Han K, et al. Among authors: paff m. Clin Pharmacol Drug Dev. 2022 Oct;11(10):1191-1202. doi: 10.1002/cpdd.1154. Epub 2022 Aug 16. Clin Pharmacol Drug Dev. 2022. PMID: 35971951 Free PMC article. Clinical Trial.
Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region.
Han K, Ito H, Elston R, Cremer J, Hood S, Paff M, Theodore D. Han K, et al. Among authors: paff m. Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0090022. doi: 10.1128/aac.00900-22. Epub 2022 Dec 12. Antimicrob Agents Chemother. 2023. PMID: 36507675 Free PMC article. Clinical Trial.
The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, Wurster JA, Wilson LJ, Fyfe JA, et al. Furman PA, et al. Among authors: paff m. Antimicrob Agents Chemother. 1992 Dec;36(12):2686-92. doi: 10.1128/AAC.36.12.2686. Antimicrob Agents Chemother. 1992. PMID: 1336341 Free PMC article.
Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.
Condreay LD, Jansen RW, Powdrill TF, Johnson LC, Selleseth DW, Paff MT, Daluge SM, Painter GR, Furman PA, Ellis MN, et al. Condreay LD, et al. Among authors: paff mt. Antimicrob Agents Chemother. 1994 Mar;38(3):616-9. doi: 10.1128/AAC.38.3.616. Antimicrob Agents Chemother. 1994. PMID: 7515609 Free PMC article.
In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.
Cullen JM, Smith SL, Davis MG, Dunn SE, Botteron C, Cecchi A, Linsey D, Linzey D, Frick L, Paff MT, Goulding A, Biron K. Cullen JM, et al. Among authors: paff mt. Antimicrob Agents Chemother. 1997 Oct;41(10):2076-82. doi: 10.1128/AAC.41.10.2076. Antimicrob Agents Chemother. 1997. PMID: 9333028 Free PMC article.
76 results